Login to Your Account

Rising from the Ashes

MDCO's Cangrelor Succeeds in Phase III PHOENIX Study

By Jennifer Boggs
Managing Editor

Thursday, January 10, 2013
Despite a clinical setback in 2009, when two massive Phase III trials of cangrelor were halted for lack of apparent efficacy, the antiplatelet candidate is back on track, as The Medicines Co. reported positive results from a new Phase III study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription